CA1265964A - Implantable electrophoretic pump for ionic drugs and associated methods - Google Patents

Implantable electrophoretic pump for ionic drugs and associated methods

Info

Publication number
CA1265964A
CA1265964A CA000479337A CA479337A CA1265964A CA 1265964 A CA1265964 A CA 1265964A CA 000479337 A CA000479337 A CA 000479337A CA 479337 A CA479337 A CA 479337A CA 1265964 A CA1265964 A CA 1265964A
Authority
CA
Canada
Prior art keywords
reservoir
membrane
pump
implantable
electrodes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000479337A
Other languages
French (fr)
Inventor
Nabil I. Rizk
Charles L. Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA000479337A priority Critical patent/CA1265964A/en
Application granted granted Critical
Publication of CA1265964A publication Critical patent/CA1265964A/en
Expired legal-status Critical Current

Links

Abstract

ABSTRACT OF THE DISCLOSURE
An implantable electrophoretic pump for ionic drugs and the method of using the same is provided. A reservoir is provided with a filler opening and a discharge opening. The discharge opening has a diffusion membrane and a pair of associated electrodes. A battery and electronic components provide for energizing the electrodes so as to effect ion transfer of the ionic drugs into other portions of the patient's body through the voltage induced between the two electrodes. The pump is particularly useful for ionic drugs such as insulin, blood thinners, antibiotics and the like. A method of making a porous electrode.

Description

IMPLANTABBE ELECTROPHORETIC PUMP FOR
IONIC DRUGS AND ASSOCIATE~ METHODS

BACKGROUND OF THE INVENTION
1. Field of the Invention This invention relates to an implantable, molecular electrophoretic pump for ionic drugs and, more specifically, it relates to a durable and improved pump which is adapted to - supply, on a predetermined basis, desired quantities of medication.
2. Description of the Prior Art It has beén known that medicines may, in many instances, be employed more efficiently by providing a pump to , deliver the medication to a patient at a more uniform rate than wouId be experienced by periodic injections through syringes.
Such~pumps have been provided with the capability of either being mounted externally of the body or implanted in the body. See generaliy Electronic Flow Rate Controller for Portable Insulin Infusion Pump~by~R. T. Ferguson et~al., Diabetes Care, Vol. 3 No.
~: ~
2, March-April 1980 pp. 332-337; A Totally Implantable Drug - Infusion Device:~ Laboratory and Clinical Experience Using a Model ~With~Single~Flow Rate and New Design for Modulated Insulin and , ~ Infusion by Henry Buchwald et al., Diabetes Care, Vol. 3 No. 2, ~March-~April 1980, pP. 351~358~ Implantable Drug-Delivery Systems by Perry J.`Blackshear pp. 66-73, Scientific American 241 (December 1979); and H. Buchwald, A Two-Phase Fluid Powered `:
~Insulin Infusion Pump with Basal/Bolus Capability Which ,, :
:

Compensates for Pressure and Temperature Variability, Trans. Am.
Soc. Artif. Internal Organs, 27, 263-40 (1981).
U. S. patents 3,894,538 and 4,140,122 disclose multi-chambered medicine supplying pumps which involve actual transfer of solution and require the use of moving parts.
U. S. patent 4,140,121 discloses an implantable dosing device which delivers' drugs plus liquid and involves a variable volume medicine reservoir and a liquid chamber which is subject'ed to variations in volume through transport of liquid by electro-osmosis.
One of the problems experienced with the prior art systems has been the need to use a system having movable parts, thus rendering the pump susceptible to breakdowns and also requiring large power consumption.
In spite of the foregoing teachings, there remains a need for a self contained, refilla~le, externally programmable, implantable drug infusion device.

- SUMMARY OF THE INVEN~ION
~ The present invention has solved the above-described problems~by providing a self-contained, refillable, externally ~programmable, implantable ionic drug dispensing electrophoretic ~pump.~ It provides a sealed housing and a reservoir having filler and~discharge openings. The filler opening may be sealed by a self-sealing member which is adapted to be pierced by a reservoir ~charging instrument, such as a hypodermic'needle. The discharge ~opening is adapted to permit the flow of ions therethrough. The discharge opening preferably has a passive diffusion membrane and "` : :
2.
``: ~ ' ~:
. ~ .

i96~
-3~- 71548-20 a pair of associated electrodes. Battery means eneryize the electrodes and cooperate with elec-tronic means so as to pro-vide delivery of ions at the desired rate.
In one embodiment of the invention, diffusion will be the principal source of ion distribution during periods when electrodes are not energized. When the electrodes are energized, depending upon the polarity of the electrodes as compared with the nature of the ion, the rate of flcw by diffusion will either be enhanced or retarded. ~lso, in a preferred embodi-ment the amount of flow initiated by energizing the electrodescan be increased for periods of unusual need.
The invention also encompasses a method for accomp-lishing distribution of ionic drugs~
~ n accordance with the present invention, there is provided àn implantable electrophoretic pump for ionic drugs comprising, a sealed housing, a reservoir having a filler opening and a discharge opening, sai:d housing having opening means operatively reservoir associated with.said filler opening and said discharge opening, a filler member disposed within said filler opening and being self~sealing and adapted to be pierced by a reservoir filling member and upon removal of said filling member will resist leakage therethrough., a reservoir discharge member disposed within said dischaxge opening and having a diffusion membrane and a pair of assoc-iated eIectrodes, electrical energizing means for energizing said electrodes, and . ~

.. . . . ..

`` ~26~ 7l54g-20 the polarity of said e].ectrodes being adapted to be connected such that when said electrodes are energized increased flow of said ionic drug through said discharge member will occur as compared with :Elow induced solely through diffusion when said electrodes are not energized.
In accordance with another aspect of the invention, there is provided a reservoir for an implantable electrophor-etic pump including a hollow body defining a storage chamber, a filler opening defined within said body, a self-sealing member sealingly secured within sai.d filler opening, a discharge opening deEined within said body, a diffusion membrane sealingly secured within said dis-eharge opening, and a pair o~ eleetrodes operatively assoeiated with said diffusion membrane.
In aecordanee with another aspect of the invention, there is provided a method of delivering an ionic drug eomprising providing an implantable eleetrophoretie pump having a housing within whieh is disposed a reservoir having a filler opening sealed by a self-sealing membrane and a discharge opening sealed by a diffusion membrane having eleetrode means operatively assoeiated therewith, introdueing an ionie drug into said reservoir, implanting said pump, ef~f~eeting basal rate delivery of said ionie drug by diffusion, and ' , - 3a -:

:

~X ~ 71548-20 periodically energizing said electrode to effect alteration of the diffusion induced flow of ions out of said reservoir.
It is an object of the present invention to provide a reliable means for delivering efficiently, predetermined quanti-ties of an ionic medication by means of an implantable pump.
It is a further objec-t oE the invention to provide such a pump and a method of using the same w~erein durability and dependability of the pump are enhanced as a result of the absence of moving parts.
It is another object of the present invention to provide such an implantable pump which may be programmed externally.
It is a further object oE the present invention to provide such a pump which requires very modest electrical energy to operate in the predetermined manner.

~ ~ , :: :

:: :
; ~ - 3b -"
- . , .

~GS969L

It is yet another object of the invention to provide such a pump which may have its reservoir replenished by means of a hypodermic needle without the need for a surgical procedure.
It is a further object of the present invention to provide such' a pump which is adapted to be used with a number of different types of ionic drugs.
It is a further object of the present invention to provide such a pump which is adapted to be employed in the delivery o insulin to diabetic patients.
It is yet another object of the invention to provide means for delivering an extra dose of the medication during periods of unique needs.
These and other objects of the invention will be more fully understood from the following description of the invention on reference to the illustrations appended hereto.

BRIEF DESCRIPTION OF THE DRAWINGS
Figure I is a schematic illustration of a principlé of the present i~nvention.
Figure 2 is a plot of a relationship between diffusion and electrophoresis.
.
Figure~3 is a plot of delivery rate versus current.
~ Figùre 4 is a perspective view o a form of pump of the pr~esent invention.
~ Figure~5 is a partially schematic top plan view (with a top wall not shown) of an embodiment of the present invention.
Figure 6 is a cross-sectional illustration of the system of Figure 5 taken through 6-6.

~ 4.
:~

Figure 7 is an exploded view of a form of collar and reservoir of the captioned invention.
Figure 8 is a generally cylindrical orm of reservoir of the present invention.
Figure 9 is a partially exploded cross-sectional illustration of a form of filler membrane assembly of the present invention.
Figure lO is a fragmentary cross-sectional view showing a portion of the discharge opening of the reservoir.
Figures ll through 13 show sequential stages of a method of making a porous electrode of the present invention.
Figure 14 is a schematic illustration of another embodiment wherein the reservoir is positioned exteriorly of the housing.
Figure 15 is a schematic illustration of a portion of the electronic components of the pump.

DESCRIPTION OF T~E PREFERRED EMBODIMENTS
As used herein, the term "ionic drug" means ionically charged materials adapted for medical uses within a human or anlmaI and shall expressly include, but not be limited to, insulin, peptide hormones, blood thinners, neurotrophics, antibiotias, analgesics, immunosuppresive agents and pharmaoeutioal materials modified to carry a charge.
As used~herein the term "patient" shall be deemed to include humans and animals.
Referring now to Figure 1 in greater detail there is ~shown~;schematically a reservoir of the present invention and the '' ~ 5.

~.Z65~

manner in which the ionic drugs will be passed through the discharge opening so as to emerge from the pump and be delivered to the patient for absorption. The reservoir 2 is hermetically sealed and has a reservoir chamber 4 which contains the ionic drug or drugs to be dispensed. The drugs may conveniently be in the form of a suspension. Discharge opening 6 is provided with a passive membrane 8 which will permit ions to pass therethrough.
This membrane 8 preferably also resists passage of bacteria therethrough The membrane 8 may be a cellulose membrane. Among the preferred materials that are suitable for use as the membrane 52 are those made from cellulose esters, nylon polyvinylidene flouride, polytetrafluoroethylene, cellulose nitrate and acetate and mixtures thereof. The preferred membranes have pore sizes - ~ from about 0.025 to 8 microns and are from about lO0 to 200lS microns thick. The membrane diameters are preferably between about l3 and 293 millimeters. In general, many types of microfi1tration membranes may be employed. Among the preferred materials are those sold under the trade designations "MF"
.
tMillipore): "Ce1Otate" (Mill1pore); "~urapore" tMillipore);
"Diaflow"~ (Am1con); "Mitex" tMillipore); and "Fluoropore"
(Millipore).
The electodes are preferably composed o a material selected from the group consisting of silver/silver chloride, ::
carbon, carbon mesh and platinum.
~ Disposed on opposite sides of the membrane 8 and operatively associated therewith are a pair of porous electrodes 10,~12~which will be described in greater detail hereinafter. A
~;battery~14, by means of anode lead 16 and cathode lead 18, :
~ 6.

~: :
, 2G~g~ , energizes the respective electrodes 10, 12. In this arrangement, if insulin w~re contained within the chamber 4, as insulin is a negative ion, the membrane 8 will permit passage of the ions through the same. The direction of movement caused by electrophoresis with the electrodes energized as shown indicated by the arrow "E".
Under normal circumstances, the buildup of concentration of ions in the reservoir 4 will result in passage of the material through the membrane 8 in the direction indicated by the arrow ~D~ even when the electrodes are not energized.
This diffusion flow may be relied upon, in some instances, as establishing a basic rate for ongoing delivery of the ionic drugs. In some cases, as may be true with insulin, it may be desirable to provide a greater flow than would occur through diffusion in which case energizing the electrodes 10, 12 serves to increase the rate of delivery of the material. If desired, for certain~materials, means may be provided for reversing remotely the polarity of electrodes 10, 12 thereby causing the ~ electrophoresis to retard the amount of ionic flow effected ~-through diffusion.
EXAMPLE
~ ~ ~In order~ to provide further understanding of the invention the~following example is provided.
::
; A housing, made of titanium, having the shape illustrated in Figure 4 is provided. The housing has a height H
of~about 18~mm.~,~a length L oP about 10 cm, an average width W of , ~
~about 40 mm and a wall thickness of about 0.5 mm. The reservoir ~is made~;of titanium and has a continuous interior coating of , ~ :
~ 7.

, . . . . .
, . . . . .

~26~

silicone rubber about l/lO mm. thick. The reservoir is cylindrical in shape with a diameter of about 35 mm. and an average height of about l9 mm. The reservoir is secured in the housing and has about l gram of insulin in slurry form in its chamber. The insulin may be crystalline insulin suspended in ~aCl based buffer with extra crystals suspended in a matrix of trimethyl cellulose. The total insulin is present (slurry plus undissolved solid) in quantities of about 25 mg/ml and the reservoir holds about 25 ml. A unit of insulin weighs about 1/24 mg.
Two 2.7 volt lithium iodide batteries energize a pair of carbon mesh porous electrodes which are on opposite sides of a `cellulose acetate passive membrane having a thickness of about 150 microns and a cross sectional area of about 0.5 cm2. A
voltage of about 1.2 volts is imposed across the electrodes.
Direct current or pulsed direat current are preferably employed. The filler membrane is composed of reinforced silicone rubber and has an area of about 1 1/2 cm2.
The system, when the electrodes are energized, operates at about 1-15 milliamperes.
The electronic unit turns the pump on and off during ~predetermined periods with diffusion induced flow continuing at a basic~rate when the electrodes are not on.

~ Before turning to further details of the invention, the backgrouad will be considered. The electrophoretic ion pump ~utilizes the phenomenon of electrodiffusion for the transport of 8.
~ .

~2~;96~

an ionic drug from a reservoir to the surrounding body tissue.
The phenomenon involves a combination of diffusion and electrophoretic transport.
501utions consist of molecules dissolved in a solvent. It sometimes is convenient to regard one or more components as solute and the other the solvent. 30th solvent and solute molecules are in constant motion with respect to each other and in constant collision, as long as the solution remains liquid. If an interface is formed between the solution and pure liquid solvent and if this interface remains stable, solute molecules will be transported across the interface from solution to solvent. This process, if left undisturbed, will continue until the concentration of solute becomes the same throughout.
Net transport will cease, and the system will be in equilibrium. This mode of transport is called "free diffusion".
90metimes in the process of free diffusion, it is difficult to stabilize the interface between solution and solvent, Because this can be troublesome, a porous membrane is sometimes placed between solution and the solvent, forming the i~nterEace. Difusion, then, takes place within the pores of the membrane. AIthough the rate of transport is usually diminished, the phenomenon is still basically difusion.
If the solute molecules happen to be larger than the ~ ~ pores~of the membrane, they are excluded and will be retained in the solution side of the boundary, If there is a mixture of :
;~molecules~both larger and smaller than the pores, the smaller ones w.ill pass through the membrane and the larger ones will be ret~ained. In the~electrophoretic ion pump, the membrane will ~L2G5964 pass the solvent (water) of body fluids, the inorganic salts, organic acids, sugars and most proteins. As only the ionic drug will be supplied within the reservoir, all these components of body fluids will quickly equilibrate with the reservoir so there will be no or little net transport of these substances of body fluids during operation of the pump. This concept will be referred to herein as employing a membrane whiah will readily pass the ionic drug therethrough. The pump of the present invention may be considered a molecular pump as distinguished from a bulk pump. The pump has pressure equilibrium with the result that it does not induce the flow of fluids.
The process of diffusion is basically the same for molecules that carry no net electrical charge as for ions. With respect to molecules that are capable of penetrating the membrane, if their rates of diffusion are diminished to the same extent, the membrane is said to be passive. If, on the other hand, the membrane affects different kinds of molecules to different extents, the membrane is permselective (or an "active membrane")O The most common kind of permselectivity arises with ionic solute molecules and immobilized eiectric charges in or near the pores ~of the membrane. In this case, the ion carrying a ;charge of the same sign as the immobilized ones will be inhibited ~;
or~exal~uded rom the membrane. The ion carrying a charge of the opposite sign will be transported with little or no inhibition.
~ The pump~of the present invention preferably utilizes a passive membrane, but permselective membranes may be used for transport of particular ionic drugs.

... . .

~Z~5~6~

It is generally not satisfactory to rely solely on the process of diffusion for a drug delivery system. This is because the rate of delivery depends upon the physical and mechanical properties of the membrane which are not alterable conveniently. This me~ns that one has virtually no control of the drug delivery rate. In ~he case of insulin delivery, moreover, the pump may have to operate at two different delivery rates, changing from one to the other several times a day such as meals, for example. If ~he drug molecules are ions, however, delivery can also be achieved through electrophoresis.
Electrophoresis can be best understood in terms of an example. Consider a pair of parallel flat electrodes immersed in a solution containing ions. If a certain voltage is applied to the electrodes, a current will flow in the space between them.
The ions in solution move, those with positive charge moving toward the cathode (cations) and those with negative charge moving toward the anode (anions). This flow of ions constitutes a flow of electric current. The rate of flow of the ions depends on the slgn and magnitude of the electric charge that they carry, the~ physical size of the ion, the voltage placed across the cell, and the distance of separation of the electrodes. Because some of~t~ese~properties are properties of the apparatus and not the molecule~ being transported, it is customary to define a quantity called mobility (u) as the velocity (v) imparted to a specific ~ion per unit of~electrical field strength E/L or ln symbols, (1) u = vL/E

~ : `
.

,- , ~26~4 Where E is the voltage drop and L is the separation distance between electrodes~ Mobility is a property of the ion which can be measured. If the mobility of the anion is u_ and the mobility of the cathion is u+, then the fraction of the total current carried by the ions is (2) t = u /tu +u+) and t~ = u~/(u_+u+) The fraction of the total current carried by the anions, t , and cations t~, depends upon their respective mobilities. In general, these are different numbers. However, the important point is that the current is carried by ions in solution, the fraction depending on their mobility, and that anions such as insulin move to the anode and cations move to the cathode. The ions are moving because they are being produced in the vicinity of one of the electrodes and being consumed at the other, resulting in a flow of ions. It is not proper to think of the ions being attracted or repelled electrostatically to the electrodes, as electrons are in space. This means also that if an ion should~find itsel, for instance, on the side of the anodej~facing away from the cathode, it will be neither attracted nor~repelled from it because there is no current flowing in the vlcinity: as current flows only between the electrodes.
The rate of movement of the ions depends upon the voltage~across the cell, among other things. This, however, is a very desi~rable~property because it allows one to control the rate , ~ ~ ~of movement by controling a voltage. While it is difficult to 12.
:; :

-:

~G~96~ 715~8-20 change the physical or mechanical properties of a device, it iB
usually easy to change the voltage across a cell.
It is a feature of the present invention to provide an ionic drug delivery device working on the principles of both diffusion and electrophoresis telectro~if~usion) wherein the rate can be controlled electrically.
The transport of molecules from the combined forces of electrical and diffusive forces has been described by Planck and Nernst in the last century. For most situations, and especially for passive membranes, the treatment is still adequate (although now it is known to be inadequate for certain cellular and subcellular membranes). The behavior of molecules under free diffusion and electrophoresis can be summarized in the following partial differential equation.

(3) ~c = uE ~c ~ D' L ~ ~x where c is concentration of the transported molecule at some position, x, between the electrodes and at some time, t. For the other variable, u is the mobility of the ion, D' is its diffusion coefficient, and E is the electric field strength.
The diffusion coefficient is primed because with a membrane it is different than for free diffusion D' = D(l-~) where the factor (1-~) incorporates this. With resp~ct to the transport of insulin values for c, u and D will be those for insulin.
Solving this differential equation for the case of material transport across a membrane, for the steady state, the so1ution is glven by equation (4).

~2659~ 71548-20
(4) J = uEc- ~ u2 ~
~ ~J

where J is the delivery rate (in g cm~2 o~ membrane/sec~l), where ci is the concentration of the drug (insulinj in the reservoir of the pump, and u is -the mobility of the ion being transported, already defined. U is a function which depends on some parameters of the drug and on the delivery system.
This is shown by equation (5).
(5) U = eU~h/2LD' In this equation h is the thickness of the membrane.
For æero current density, equation (4) reduces to that for diffusion only. For currents resulting in pumping the drug out of the re~ervoir tnegative currents), and for high current denslty, the function U in equation (5) is much larger than 1 and equation 4 reduces to
(6) J = ~

Here, l~ l:S the current density (in amperes cm~2), and S i8 the specific conductivity of the mediu~ containing the drug (in mho cm~~ In this case, the specific de].ivery rate does not depend on the di~fusion coefficient, D'. This means that, when operated at high current density, transport is by electrophoresis~only and diffusion is not important.
For small currents, equation (4) reduces to
(7) ~ J = cl ~ ~ hD ) .
, :.- .

~ 71548-20 This means that, for small current density, the spec~fic delivery rate varies in a linear fashion with current density.
Figure 2 is a dimensionless plot of equation (4) in which the specific deliver~ rate relative to the ~ero current rate (i.e., diffusion alone) is plotted against the ~unction Rx. Here Rx is a dimensionless function defined as uhi/SD'. Rx depends upon constants of the system and current density. When the constants in equation (4) are known, Figure 2 can be employed to calculate the fundamental relationships describing the operation of the pump for various drugs and for various operating conditions. It can be seen that for positive current ("pumping in"), the delivery rate is less than for diffusion alone and it rapidly approaches zero with increasing current. For negative current ("pumping out"), the delivery rate is larger than that for diffusion alone. In the linear portion of the curve, the pump is operating by elec-trophoresis primarily with diffusion not being significant.
A phenomenon called "polarization" generally prevents the use of electrodes such as carbon to produce a direct current although they would be acceptable with pulsed DC or alternating current. As soon as current begins to flow, the electrode products collect in the vicinity of the electrode surface and create a back voltage. Sometimes this back voltage is as high as the driving voltage and current will not flow.
We have developed a method whereby this problem can be avoided in an electrophoretic pump. The degree of polarity depends upon the current density in the electrode surface. The half-time for decay of this polarity, however (with the electrodes shorted) does not. Since the region of the polarity about the electrode ~ - 15 -. .

~2~ 715~8-20 surface is very thin, the decay time is very short . Thi6 means that by making khe electrodes with a very high surf~ce area, total curren-t can be high but current density at the electrode surface kept low. Further, it means that polarization will occur slowly and depolarization will be fast. Thus, we use a pulsed DC power system (as described hereinafter) in the pump, generating reasonable current while avoiding serious polarization problems. The current will flow until the polarization hits an upper limit, then will stop for a relatively short time to allow depolariæation. Then, the cycle will repeat. Our experiments with porous graphite electrodes show that 5 milliamperes of current can flow for 1 minute before the voltage rises to 1 volt. The electrodes depolarize in about 10 seconds or less.
To create pulsed DC, the voltage across the membrane may be monitored through a Comparator circuit. When the voltage reaches a predetermined value, the Comparator output changes. The Comparator output is used to turn off the DC
source for a predetermined time. When the time is exhausted, the Comparator output is reset, and the cycle resumes from the beginning. The circuit resembles in operation a free running multivibrator (analog form) where the current charging a capacitor while monitoring the voltage and starts to discharge the capacitor when it reaches a certain value and stops discharge when it reaches other values.
Shown in Figure 3 is the relationship between the current resulting from a particular potential level applied to the eleotrodes as plotted against the specific delivery rate of ., : , the ionic drug. Plot A is a theoretically developed relationship. The minus current indication with respect to current is to represent electrode polarity as shown in Figure 1 and the positive current is the reverse direction. When the S current of the experimental system was at zero, diffusion was the sole means of transport of ionic material out of the reservoir.
Ion transport was effected at the level B. In other words, without energizing the electrodes an ionic flow equal to 0.5 units of the ionic drug, (which in the experimental case was bovine serum albumen, which can readily be correlated with insulin), per square centimeter of passive membrane area per hour resulted. When a negative potential is imposed on the electrodes a resultant current flows through the liquid between the electrodes. As the magnitude of the current is increased in the negative direction, the rate of delivery of the i~nic material through the membrane is proportionately increased. When the current reaches the level of -3 milliamperes the rate of delivery increases from 0.5 units/cm2/hrs to 1 unit cm2/hr. Similarly, when the polarity of the electrodes is reversed, the current ~0 imposes a retarding effect as electrophoresis action tends to ~oppose the;diffusion. As a result the net delivery rate drops ::
below the rate~for diffusion without any imposed current. It is noted that the delivery rate did not reach zero even when the current reached 6 milliamperes.
~ Referring now to Figure 4 there is shown the pump of ~ one embodlment of the present invention. It has an exterior ~: .
- ~ housing which is preferably sealed and provides suitable openings or refilling and discharge of ions. The housing is preferably 17.
~:

~ 2~

made of a suitable inert material which will possess adequate strength. Amon~ the suitable materials are titanium, medical grade stainless steel and reinforced polymers. The size and shape of the pump should be such that it is compatible with the portions of the body in which it will be implanted. In the form illustrated, the pump is generally triangular with rounded corners and has a top wall 32, a lateral wall 34 and a bottom wall (not shown) essentially identical to the top wall but without an opening. The top wall has filler opening 36 and the lateral wall defines discharge opening 38. In a preferred embodiment of the invention the pump will have an overall length L equal to about 90 mm to 110 mm, a height H equal to about lS mm to 25 mm and width W equal to about 35 mm to 50 mm. Shown positioned within the top opening 36 is a self-sealing filler membrane 50 which will be described in greater detail hereinafter. Disposed within discharge opening 38 is the passive discharge membrane 52.
Referring now to Figures 5 and 6, the interior arrangement of the pump will be considered in greater detail. In general, in the form~illustrated, the pump interior has three sections. The reservolr 56 is positioned at the narrow portion of housing 30, the~electronic compartment 58 ls disposed adjacent to~the reservoir 56 and the batteries 6n, 62 are positioned within the enlarged;end of the housing. Electrical wires 64, 66 carry electricity from the batteries 60, 62 to the electronic unit sa which includes a high value capacitor ton the order of about 3 to 5 farads, for example). These capacitors function as àn electrlcal energy reservoir. This is needed because lithium 18.

, :

.' ' ~,' "' ', j59~

iodide batteries do not provide the required current during periods of unusually high demand ("bolus") and they have a high internal impedance. These capacitors would not necessarily be required for batteries with low internal impedance such as Li-CuS
batteries, for example. Wires 68, 70 permit the batteries 60, 62 to energize the electrodes by way of electronics unit 58 (with the electrical connection between the two not illustrated). As is shown the wires 68, 70 are preferably wound around reservoir 56. These wires are used as antennas to transmit and receive information from an external programmer. Internally the signals may be fed through blocking capacitors to the communication circuitry.
The reservoir 56 provides a sealed chamber for storage of the ionic drugs. Preferably it has a storage capacity of about 15 to 25 ml. In the form illustrated, the reservoir is of generally cylindrical configuration and has an opening 72 in the upper wall which sealingly receives filler membrane 50 and an opening 74 in the Iateral wall which receives the passive~
membrane 52. As is shown in Figure 4, the membrane 50 is exposed ~0 through opening 36 in the top of the housing 32 and membrane 52 is exposed through opening 38 in the housing 32. In the form illustrated the housing openings 36, 38 and the corresponding resevoir openings 72, 74 are, respectively, disposed on surfaces ~oriented generally perpendicular to each other. This arrangement prevents piercing of the delivery port by the filler needle, thereby obviating the need for a needle target. For example, assuming the embodiment illustrated in Figure 6 is surgically implanted in the peritoneum of the patient with the membrane 50 ~ ~: 19.

~ ~9~

closely adjacent to and facing the skin, a minimum path of travel for a hypodermic syringe is provided for convenience in filling. Also, discharge of ions through the opening 52 will direct the ions into the surrounding tissue of the patient.
In order to minimize contact between the ionic drug or ionic drug containing solution or slurry with the interior walls of the reservoir 56 the interior may advantageously be provided with a suitable coating material such as silicone rubber, for example. A suitable material is that sold under the trade designation Silastic. If desired, an immobilized ionic group such as a suitable ion exchange resin may be employed to resist precipitation and adhesion of the ionic drug to the reservoir wall.
The present system is adapted to be operated at a low current level. This provides several advantages. It enables the use of batteries which under such service conditions will have a very long life, thereby minimizing the frequency with which the implantable device must be surgically removed in order to replace the~batteries. Also, the pump housing may be maintained at the desired small size. A suitable type of battery for use in the present system is the lithium iodide cell which may have a voltage of about 2.7 volts (beginning of life) to about 2.1 volts ` (end of life). ~These batteries have proven to be successful in ~ the~connea~tion with use in cardiac pacemakers. See generally, ~ The Lithium Iodide Cell - History by Dr. Alan A. Schneider et ~ ::
al.,~Medical Electronic ~ Data, January-February 1977, pp. 48-51.

..

20.

As the electronic means 58 may take the form of known solid state systems or any alternate means which would be readily apparent to ~hose skilled in the art, a detailed disclosure of the same need not be provided herein. Also, numerous external programmers are known to those skilled in the art. See generally Christionsen et al., J. Clinical Lab. Invest. 41(z), pp. 674-654 (Nov. 1981); Geisen et al., Res. Exp. Med. (Bev); 179(2), pp.
103-111~ l9Bl; and W. Burns et al. Inn. Med. 36(17), pp. 625-627 (Sept. 1981). In general, such systems involve setting a basal program based on timing principals such that the batteries 60, 62 of the present system will energize the electrodes adjacent membrane 52 at a certain current level for a predetermined period of time at predetermined times during the day. At times the system will either be at an "off state~ wherein transport of ions continues by diffusion only. Also, an emergency or larger demand situation (bolus") may be provided for. In addition, in the emergency situation the patient may activate the system so as to provide a single cycle of operation at a predetermined emergency or bolus level to dispense addltional quantiti~s of the ionic drugs, soch as durin~ meal times, for example. One manner in which this~might be accomplished is by having the patient hold a magnet ln close proximity to the unit for a predetermined time.
~ As a convenient means for providing extra insulin, for example to avert hyperglycemia, this externally activatible bolus :~ :
~system may have a magnetic reed switch in the electrical circuit of the~pump. ~The switch when in ~off" position may be moved to the nonn position by application of a magnetic field of a predetermined minimum intensity for a predetermined period This 21.

9~

. minimizes the risk of accidental triggering of the pump by stray magnetic fields. In general, the programminy is so established as to preclude emergency activation beyond the given number of times within a twenty-four hour period in order to prevent overdosing of the patient. It is also preferable, in general, to have the programmer such that it can be programmed only by the physician and not by the patient.
In providing insulin to a diabetic patient, for example, the average daily dose will be about 1 unit /kg of body weight. A unit of insulin is about 1/24 mg. A patient requires about 40 to 80 units a day. The pump will be set to deliver a portion of this by diffusion with the electrodes not energized and a portion to be delivered electrophoretically, with possible additional energizing amounts delivered by bolus action. The reservoir will preferably hold about a 250 day supply for an average patient.
~eferring once again to Figure 5, in the filler opening 72 a plurality of radially oriented reinforcement struts 78 are preferahly molded into the membrane in order to reinforce the same.
Figures 7 through 9 show further refinements of a preferred reservoir arrangement. The reservoir 2 has the upper wall 90 which contains opening 72 and the filler membrane 50. A
lateral wall 92 is provided with the discharge opening 74 and a bottom wall ~not shown) which is substantially of the same size and shape as the top wall 90 and may be imperforate. As is shown in the exploded view of Figure 7, a collar member 94 is provided with a tubular portion 96 and a lower radially extending flange 22~

.

6~

portion 98. The flange portion 98 is adapted to be secured to the upper wall 90 such that the bore of tube 96 is generally aligned with opening 72. After positioning of the membrane in place and securement of the member 94, the upper portions of the collar tube 96 are deformed downwardly and inwardly over the membrane 50. This securement may be effected by any desired means such as adhesive bonding. Collar 94 facilitates manual location of membrane 50 for refilling.
Figure 9 shows a convenient means of creating the membrane construction. A mold member 100 having an upwardly facing recess is placed in underlying contacting relationship with respect to wall 90. The strut members 78 are placed in the desired reinforcing position and the membrane material in molten state is poured into the assembly so as to create the desired structure. This serves to seal the opening 72 while permitting penetration therethrough by a hypodermic syringe employed to refill the reservoir. As is shown in Figure 7, a membrane frame 110 is adapted to hold the electrode membrane assembly which permits discharge of ions through opening 74.
~eferring to Figure 10, details of the preferred assembly~ and the d~ischarge opening 74 will be considered. The reservoir, which may advantageously be made of a suitable metal such~ as titanium, has the protective titanium shroud 110 secured to~the peripheral walI 92 thereof in surrounding relationship with respect to the membrane 52. The assembly, which consists of a pair of porous electrodes and interposed passive ionic membrane which permits passage of ions, will be considered. A generally channel shaped electrically insulative Çrame 112 which may be .
~ 23 ~.- :

/

9~

made of polytetraflouroethylene, secures a pair of metal frame members 114, 116. A pair of carbon mesh electrodes 120, 122 are positioned inwardly of the frame members 114, 116. The membrane 52 is separated from the electrodes 120, 122 by suitable annular 5 electrical insulators 124, 126. A suitable adhesive may serve to both seal and secure the assembly lead. Electrical leads from the battery 60, 62 by way of the electronics means 58 serve to energize the electrodes with one lead functioning as a positive electrode and the other as a negative electrode. In those instances where a negative ionic drug is being dispensed by the pump the innermost electrode 120 will have a negative charge and the oatermost will have a positive charge. The electrodes will produce an electrochemical potential gradient, as these ions carry a net charge, they are subjected to forces which cause them ; 15 to move in the field. The anions move to the anode and cations to the cathode.
Referring to Figures 11 through 13 a method of making a porous electrode for use in the present invention-will be consi~dered. The porous electrode provides the advantage of increased surface area. A suitable electrically insulative ~support material~such as polytetrafluoruethylene, medical grade, epoxy or~silicone rubber, for example, 120 is provided. A series ~f electrically conductive members 122, such as car~on fibers, ~: , preferably having a thickness of about l to lO microns are positioned on the upper surface of support 120 with the fibers being~generally parallel to each other. A second series of electrically conductive fibers 124 are positioned in relative ~paral~lel relationship with respect to each other and are oriented , ~ .
~ 24, ;9~

generally perpendicularly with respect to the other series df-fibers 122. An electrically conductive frame member 130 composed of a material such as platinum, medical grade stainless steel or carbon paste, for example, is then secured in electrically conductive overlying relationship with respect to underlying mesh of fibers 122, 124. Lead wires 126, 128 from the electronics unit 58 are electrically connected to the mesh of fibers 122, 124 through the conductive frame 130. A pair of such frames is used in the construction shown in Figure 10.
Referring to Figure 14, an alternate embodiment of the invention will now be considered. In this embodiment the reservoir 140 rather than being positioned within the housing 142 is remotely positioned with respect thereto and is in electrical communication with the electronics units and batteries disposed within the housing 142 by means of electrical leads 144, 146. A
suitable covering layer 143 ~dotted) is provided on housing 142 and may be a silicone rubber, for example.
~As has been indicated hereinbefore, various means of effecting electronically controlled triggering of the electrophoretic~action to either boost or retard ionic drug delivery~may be employed. A preferred approach of the present invention;involves control of pumping of the ionic drug by means ~of~an~;essentially constant current applied to the electrodes for ~ ~a pr~edetermined time. The time-current combination may be ~ ~equated,~for a given ionic drug, with a predetermined quantity or ~; dosage to~be delivered. For example, if it has been determined t~hat~O.lO~unlt of insulin will be delivered by the pump when the curr`ent is~at a given current level such as about 1 to 10 , ::
~ . 25.

.

., ~2 ~ 5~ 6 ~ 715~-20 milliamps, and the pump is energized for a given period of time such as 25 to 35 seconds, the remote programmer will es-tablish a 24 hour program for the pump wherein the given amount of units desired to be delivered within that time will be delivered by using multiples of the 0.10 unit. Further, this is employed to space the dosage delivery in the desired fashion.
Referring to Figure 15, a modular unit o the electronic system of the pump and the paths of information flow will be considered. The schematic illustrated may involve a given unit of time such as two hours, for example, with twelve duplicate units being provided to cover a day. In operation, the programmer will send a radio signal which will be received by the basal (regular) demand communication register 170 and the bolus (unusual) communication register 176. The former will be provided with a signal telling it how many pulses of 0.1 units of insulin to deliver with a given time period such as two hours, for example. The latter will receive a signal telling it how many pulses of 1.0 units of insulin to deliver once it has been activated by the pa-tient as for example, before a meal. The real time clock 210 serves to provide a time reference for operation of the basal delivery system.
When the designated time for activation of the basal system has been reached the information regarding the time period during which the system will opera-te is transEerred from the basal working reglster 172 by means of path 174. Each working register 172, 178, 184 cooperates with an associated communication register and communicates respectively by path 174, 180i 186 with registers 170, 176, 182, which in turn are in receipt of signals from the external programmer.
.

.
~;, This system will permit the batteries to energize the electrodes so as to impose the current desired for the predetermined period of time which will be governed by the real time clock 210. At the end of the cycle of operation, energization of the electrodes will be terminated. Information regarding the initial quantity of the ionic drug present in the reservoir as well as the amount di charged through basal or bolus action may be stored in a separate counter. It is also desirable to have the programmer receive, upon request, signals providing information regarding the amount of material left in the reservoir. ThiS is determined by counting the delivery pulses. This register is cleared only after refilling of the reservoir in ordee to give a cumulative reading of the amount of material remaining. In this way the demands foe individual patients for insulin can be established.
. :~
The expressions Tbasal and ~bolus are the ti required to deliver, respectively, the basal and bolus levels.
The times will generally consist of a certain number of pulses such as, for example, 28 seconds for basal and 280 seconds for bolus.
.

In a bolus situationj a magnetic field is applied to the pump at a predetermined intensity for a given period of time in~order~to initiate movement Oe the magnetic reed switch so as to cause a signal to be transferred from bolus working register 178 to the output counter. Information is placed in the bolus ~flag communicatlon register 182 during programming and ~ tr~ansferred to the working register 178. The bolus flag working , register 184 permits the bolus system to be activated only a predetermined number of times during the day in order to avoid , ~ ~ 21.

the patient dispensing an excess amount of insulin by bolus activation For example/ if it were determined that a patient should be permitted a maximum of four bolus cycles per day, each time the flag working register 184 is set by the programmer and the magnet reed switch is activated by the patient, the bolus delivery is initiated. The delivery is terminated after a preselected number of pulses. The real time clock 210, is connected to the respective working registers 172, 178, 184, respectively by paths 196-200, 190-194-200 and 192-194-200. The real time clock 210 will have a counter which serves to automatically con~rol the duration of a bolus or basal cycle.
When the counter reaches zero the delivery by electrophoretic action would be terminated.
If desired, a glucose sensor may be provided so as to permit sensing of the glucose content of blood and providing a servo control to adjust the operation of the pump for departures from deslred glucose blood level ranges.
If~it is desired to provide a pump wherein diffusion is either extinguished or substantially min:imized during periods when the pump is not energized electrically, an active membrane such as an ion exchange membrane, for example, may be used as the dlffusion membrane.
~ While not preferred, if desirecl one could eliminate the basal rate or reduce it to zero and rely solely on bolus d~istribution.
It will be appreciated that the present invention ~provides~a self contained, refillable, externally programmable, implantable ionic~drug diffusion device which is economical to 2Y, ::
' ~ ~ , . .

~L2~

use, will be of long duration through the low power required and is of high reliability as a result of i~s lack of mechanical moving parts which would be subject to wear and tear.
While for simplicity of disclosure reference has been made previously to use of the pump with a single ionic drug, it will be appreciated that it may be used with two or more materials simultaneously.
Whereas particular embodiments of this invention have been described above for purposes of illustration, it will be evident to those skilled in the art that numerous variations of the details may made without departing from tHe invention as defined in the appended claims.

':

::
~:
' ::
: :

~: _ :
:

Claims (39)

CLAIMS :
1. An implantable electrophoretic pump for ionic drugs comprising, a sealed housing, a reservoir having a filler opening and a discharge opening, said housing having opening means operatively reservoir associated with said filler opening and said discharge opening, a filler member disposed within said filler opening and being self-sealing and adapted to be pierced by a reservoir filling member and upon removal of said filling member will resist leakage therethrough, a reservoir discharge member disposed within said discharge opening and having a diffusion membrane and a pair of associated electrodes, electrical energizing means for energizing said electrodes, and the polarity of said electrodes being adapted to be connected such that when said electrodes are energized increased flow of said ionic drug through said discharge member will occur as compared with flow induced solely through diffusion when said electrodes are not energized.
2. The implantable electrophoretic pump of claim 1 wherein said electrical means includes battery means.
3. The implantable electrophoretic pump of claim 2 wherein said diffusion membrane is a passive diffusion membrane.

30.
4. The implantable electrophoretic pump of claim 1 including said discharge member being in communication with the exterior of that housing through said opening means, and said filler member being in communication with the exterior of said housing through said opening means.
5. The implantable electrophoretic pump of claim 3 including said passive diffusion membrane permitting the passage of said ionic drug therethrough under the influence of diffusion or electrophoresis or both.
6. The implantable electrophoretic pump of claim 1 including said diffusion membrane being an active membrane.
7. The implantable electrophoretic pump of claim 6 including said active membrane being an ion exchange membrane.
8. The implantable electrophoretic pump of claim 5 including said filler opening being disposed in a first wall of said reservoir, and said discharge opening being disposed in a second wall of said reservoir.
9. The implantable electrophoretic pump of claim 8 including said first wall and said second wall being substantially perpendicular to each other.

31.
10. The implantable electrophoretic pump of claim 5 including said electrodes being of porous construction.
11. The implantable electrophoretic pump of claim 5 including said electrodes being composed of a material selected from the group consisting of silver/silver chloride, carbon, carbon mesh and platinum.
12. The implantable electrophoretic pump of claim 5 including said reservoir having a chamber with a storage volume of about 15 to 25 milliliters.
13. The implantable electrophoretic pump of claim 5 including the interior of said reservoir except for the regions of said filler opening and said discharge opening having an interior coating of a material selected from a group consisting of resinous plastic and silicone rubber.
14. The implantable electrophoretic pump of claim 5 including electronic means energized by said battery means for energizing said electrodes during predetermined periods.
15. The implantable electrophoretic pump of claim 10 including electronic means having means for bolus activation which when activated is adapted to deliver additional quantities of said ionic drug.

32.
16. The implantable electrophoretic pump of claim 15 including said bolus means adapted to be activated by means disposed exteriorly of the user.
17. The implantable electrophoretic pump of claim 14 including said electronic means having means for reversing the polarity of said electrodes.
18. The electrophoretic pump of claim 17 wherein said electronic means have means for charging the said electrode disposed closer to the interior of said reservoir with a charge of the type possessed by said ionic drug.
19. The implantable eleckrophoretic pump of claim 5 including said housing having an average height of about 15 to 25 mm., a maximum length of about 90 to 110 cm. and an average width of about 35 to 50 mm.
20. The implantable electrophoretic pump of claim 5 including said membrane being a passive membrane and said membrane being selected from the group consisting of cellulose esters, cellulose acetate, nylon, polyvinylidene flouride, polytetraflouroethylene and cellulose nitrates.
21. The implantable electrophoretic pump of claim 20 including said passive membrane having a thickness of about 100 to 200 microns and an area of about 0.5 to 5 cm2.

33.
22. The implantable electrophoretic pump of claim 5 including said reservoir being substantially cylindrical, and said filler opening being disposed on one of the end walls.
23. The implantable electrophoretic pump of claim 22 including said discharge opening being disposed in a lateral wall of said reservoir.
24. The implantable electrophoretic pump of claim 23 including said housing having a generally triangular shape in plan.
25. The implantable electrophoretlc pump of claim 1 including said reservoir disposed within said housing.
26. The implantable electrophoretic pump of claim 1 including said reservoir dlsposed externally of said housing and being in electrical communication therewith.
27. The implantable electrophoretic pump of claim 14 including said electronic means including capacitor means.
28. The implantable electrophoretic pump of claim 13 wherein said material is an ion exchange resin.

34.
29. A reservoir for an implantable electrophoretic pump including a hollow body defining a storage chamber, a filler opening defined within said body, a self-sealing member sealingly secured within said filler opening, a discharge opening defined within said body, a diffusion membrane sealingly secured within said discharge opening, and a pair of electrodes operatively associated with said diffusion membrane.
30. The reservoir of claim 29 including said diffusion membrane being a passive membrane.
31. The reservoir of claim 29 including said diffusion membrane being an active membrane.
32. The reservoir of claim 29 including said diffusion membrane being an ion exchange membrane.
33. The reservoir of claim 29 including said reservoir body being of substantially rigid construction.
34. The reservoir of claim 33 including said filler opening being in a wall oriented generally perpendicularly with respect to the wall in which said discharge opening is defined.

35.
35. The reservoir of claim 34 including said reservoir being of generally cylindrical shape.
36. The reservoir of claim 30 including said passive membrane being of a material selected from the group consisting of cellulose esters, cellulose acetate, nylon, polyvinylidene fluoride, polytetrafluoroethylene and cellulose nitrates.
37. The reservoir of claim 35 including said passive membrane having a thickness of about 100 to 200 microns.
38. The reservoir of claim 37 including said passive membrane having an area of about 0.5 to 5 cm2.
39. The reservoir of claim 37 including resilient member having reinforcing members.
CA000479337A 1985-04-17 1985-04-17 Implantable electrophoretic pump for ionic drugs and associated methods Expired CA1265964A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000479337A CA1265964A (en) 1985-04-17 1985-04-17 Implantable electrophoretic pump for ionic drugs and associated methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA000479337A CA1265964A (en) 1985-04-17 1985-04-17 Implantable electrophoretic pump for ionic drugs and associated methods

Publications (1)

Publication Number Publication Date
CA1265964A true CA1265964A (en) 1990-02-20

Family

ID=4130291

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000479337A Expired CA1265964A (en) 1985-04-17 1985-04-17 Implantable electrophoretic pump for ionic drugs and associated methods

Country Status (1)

Country Link
CA (1) CA1265964A (en)

Similar Documents

Publication Publication Date Title
US4639244A (en) Implantable electrophoretic pump for ionic drugs and associated methods
US6409698B1 (en) Perforate electrodiffusion pump
US5312325A (en) Pulsating transdermal drug delivery system
US5591123A (en) Programmable control mounting system for transdermal drug applicator
US5865786A (en) Programmable control and mounting system for transdermal drug applicator
EP0225872B1 (en) Programmable control and mounting system for transdermal drug applicator
US5224928A (en) Mounting system for transdermal drug applicator
KR930005050B1 (en) Applicator for the non-invasive transcutaneous delivery of medicament
US5135479A (en) Programmable control and mounting system for transdermal drug applicator
US5013293A (en) Pulsating transdermal drug delivery system
US4886514A (en) Electrochemically driven drug dispenser
US5746711A (en) Programmable control and mounting system for transdermal drug applicator
US4708716A (en) Transdermal drug applicator
US4505710A (en) Implantable fluid dispensing system
US4077405A (en) Apparatus for infusing liquids into human or animal bodies
US3894538A (en) Device for supplying medicines
JP2939550B2 (en) Iontophoresis electrode
DE2626348C3 (en) Implantable dosing device
US6009344A (en) Iontophoretic drug delivery system
US20030199855A1 (en) Implantable infusion device with optimized peristaltic pump motor drive
GB1602158A (en) Device for supplying a medicinal liquid to a human or animal body
CA1299457C (en) Pulsating transdermal drug delivery system
CA1308323C (en) Formulation chamber with exterior electrotransport delivery device
WO1991005582A1 (en) Iontophoresis device and method using a rate-controlling membrane
CA1265964A (en) Implantable electrophoretic pump for ionic drugs and associated methods

Legal Events

Date Code Title Description
MKLA Lapsed